CT Atlantic Overview
- Founded
- 2008
- Status
- Out of Business
- Employees
- 3
- Latest Deal Type
- Out of Business
CT Atlantic General Information
Description
Provider of drugs designed to provide treatment of cancer. The company's drugs are use to treat cancer using antibodies derived from cohorts of patients, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Wagistr. 14
- 8952 Schlieren
- Switzerland
CT Atlantic Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Oct-2018 | 00.00 | Completed | Out of Business | ||
| 1. Early Stage VC (Series A) | 12-Jan-2009 | 00.00 | 00.00 | Completed | Startup |
CT Atlantic Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Edward Stuart Ph.D | Co-Founder & Chief Executive Officer | ||
| Alexander Knuth | Scientific Founder |
CT Atlantic Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial